Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
Bio-Techne Corp Chief Executive Officer Kim Kelderman reported compensation-related equity activity, not open-market trading. On April 22, 2026, Kelderman exercised stock options to acquire 11,344 shares of Bio-Techne common stock, while 1,363 shares were disposed of to cover tax obligations at $58.58 per share. This left Kelderman with 63,058 common shares held directly after these transactions.
The filing also lists substantial remaining equity incentives, including multiple tranches of stock options and restricted stock units tied to vesting schedules and performance goals, with option exercise prices ranging from $47.60 to $120.46 and expirations extending to August 15, 2035.
Bio-Techne Corporation CFO James Hippel reported routine equity compensation activity. On April 22, 2026, he exercised stock options to acquire 62,000 shares of common stock at an exercise price of $47.60 per share. In a related F-code tax-withholding disposition, 56,097 shares of common stock were delivered at $58.58 per share to cover obligations. Following these transactions, Hippel directly owned 204,722 Bio-Techne common shares and retained substantial unexercised stock options and restricted stock units with vesting schedules extending through 2028.
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 36,500 shares of common stock at an exercise price of $47.60 per share. The options were fully exercisable and converted into an equal number of common shares.
To cover tax obligations tied to this transaction, 32,088 shares of common stock were withheld at a price of $58.66 per share, a non-market tax-withholding disposition. After these transactions, Kelderman directly owns 53,077 common shares and retains substantial unexercised stock options and restricted stock units that vest over multiple future dates.
Bio-Techne Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On April 3, 2026, he exercised restricted stock units into 2,259 shares of common stock. Of these, 740 shares were withheld at $53.13 per share to cover tax obligations, leaving him with 5,904 common shares held directly. He also continues to hold multiple stock option and restricted stock unit awards that can convert into additional Bio-Techne common shares over time.
The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting that it beneficially owns 0 shares (0%) of Bio‑Techne Corp common stock. The filing states an internal realignment effective January 12, 2026 led certain Vanguard subsidiaries to report separately, and the filing is signed on March 26, 2026.
The disclosure lists Vanguard's principal business office in Malvern, Pennsylvania, and confirms no sole or shared voting or dispositive power over the reported shares.
Crouse Steven C. reported acquisition or exercise transactions in this Form 4 filing.
BIO-TECHNE Corp executive Steven C. Crouse reported new equity awards. On March 2, 2026, he received grants of 2,387 Performance Restricted Stock Units, 735 Restricted Stock Units, and 1,911 stock options, all held directly. Each restricted stock unit represents a contingent right to receive one share of BIO-TECHNE common stock, with various vesting dates extending through 2029 tied to service and, for the performance units, achievement of specified goals.
BIO-TECHNE Corp executive Steven C. Crouse, President – Diagnostics & Spatial Biology, filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units, stock options and common stock, including 6,529 restricted stock units and 5,894 shares of common stock.
The footnotes explain that each restricted stock unit represents a right to receive one share of Bio-Techne common stock, with multiple RSU and option grants vesting in scheduled installments between 2025 and 2029. The filing does not show any new share purchases or sales, only existing awards and their vesting timelines.
Bio-Techne Corp director Amy E. Herr reported an indirect sale of common stock through her significant other. On February 17, 2026, an account held by her significant other sold 1,976 shares of Bio-Techne common stock in an open-market transaction at a weighted average price of $59.105 per share, with individual trade prices ranging from $59.091 to $59.139.
After this sale, that indirect account held 200 shares of common stock. Separately, Herr holds 2,680 shares of common stock directly, along with various stock options and restricted stock units that vest on scheduled dates between 2025 and 2029, providing additional potential future equity exposure.
A holder of Bio-Techne (TECH) common stock filed a Rule 144 notice to sell 1976 shares through Morgan Stanley Smith Barney on or around 02/17/2026 on NASDAQ, with an aggregate market value of $116791.48.
The shares to be sold are part of the company’s common stock, which had 156453292 shares outstanding listed as a baseline figure. The seller acquired these 1976 shares on 02/14/2025 by exercising previously granted stock options and paid the purchase price in cash.
Bio-Techne Corporation announced a leadership change in its Diagnostics and Spatial Biology Segment, with Dr. Matt McManus transitioning from his role and Steve Crouse, currently Senior Vice President of the Analytical Solutions Division, becoming segment president effective March 1, 2026.
Crouse’s executive employment agreement provides a $505,000 annual base salary and a target annual cash bonus equal to 75% of base pay, plus eligibility for standard employee benefits. He will receive a one-time equity grant of stock options and restricted stock units valued at approximately $170,000 in total at target, and ongoing annual equity awards with grant date values of $300,000 in stock options, $300,000 in time-vested restricted stock units, and $600,000 in performance-based restricted stock units at target. If terminated without cause, after a change in control, or for good reason, he is entitled to one year of base salary, a prorated bonus, and one year of health coverage, subject to a release of claims. The Board approved the termination of McManus’s employment without cause, making him eligible for severance under his agreement. The company highlights that it generated over $1.2 billion in net sales in fiscal 2025 and employs about 3,100 people worldwide.